Mawer Investment Management Ltd. Lowers Position in Abbott Laboratories $ABT

Mawer Investment Management Ltd. cut its holdings in Abbott Laboratories (NYSE:ABT) by 0.8% in the fourth quarter, Holdings Channel reports. The fund owned 1,245,467 shares of the healthcare product maker’s stock after selling 10,313 shares during the quarter. Mawer Investment Management Ltd.’s holdings in Abbott Laboratories were worth $156,045,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in ABT. MidAtlantic Capital Management Inc. purchased a new stake in Abbott Laboratories in the fourth quarter worth about $25,000. Harbor Capital Advisors Inc. purchased a new stake in shares of Abbott Laboratories during the fourth quarter valued at about $27,000. Guerra Advisors Inc purchased a new stake in shares of Abbott Laboratories during the third quarter valued at about $31,000. Bridge Generations Wealth Management LLC purchased a new stake in shares of Abbott Laboratories during the third quarter valued at about $33,000. Finally, Leonteq Securities AG purchased a new stake in shares of Abbott Laboratories during the fourth quarter valued at about $35,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Sanford C. Bernstein decreased their price target on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Barclays decreased their price target on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a research report on Monday, April 20th. TD Cowen decreased their price target on shares of Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Benchmark decreased their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Finally, Evercore decreased their price target on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $119.09.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The shares were bought at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the acquisition, the director owned 6,751,103 shares in the company, valued at $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Philip P. Boudreau purchased 2,200 shares of the business’s stock in a transaction that occurred on Thursday, April 23rd. The stock was acquired at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the acquisition, the chief financial officer owned 2,200 shares in the company, valued at $201,300. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. 0.46% of the stock is currently owned by corporate insiders.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $87.70 on Tuesday. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $139.06. The company’s 50 day moving average is $94.07 and its 200 day moving average is $110.31. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The company has a market cap of $152.75 billion, a PE ratio of 24.57, a price-to-earnings-growth ratio of 1.43 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter in the prior year, the company earned $1.09 EPS. Abbott Laboratories’s quarterly revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, sell-side analysts forecast that Abbott Laboratories will post 5.48 EPS for the current year.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.